This site uses features not supported by Internet Explorer.

Zantac - The Cancer Within
< Back to Webinars
Zantac - The Cancer Within

In September 2019, the online pharmacy Valisure informed the FDA that the company had found the carcinogen NDMA in some batches of the popular heartburn medication Zantac (ranitidine.) Shortly after the FDA issued an announcement, retailers pulled Zantac and generics from their shelves. Sanofi, Sandoz, and Apotex issued voluntary recalls for some lots of the drug.

Several cases have been filed around the country related to Zantac and its potential to cause cancer, mostly in federal court. The legal issues include preemption under Mensing due to generic ingestion. However, there remains potential liability against brand manufacturers in some states for ingestion of generic Zantac.

What You Can Expect to Learn

  • The plausible mechanism of action
  • Making the most of science
  • Debunking the FDA Statement
  • Establishing liability without prescription records
  • Generics and latency issues
  • Why a medical monitoring class makes sense
  • Status of filed cases
  • Litigation strategy moving forward


We're sorry you missed the webinar. You can still see a recording by filling out the form below.

Gain Access

Presented By

  • R. Jason Richards - Aylstock Witkin Kreis Overholtz
  • Kimberly Beck - Hilliard Martinez Gonzales
  • Jennifer A. Moore - Moore Law Group